(Q30593927)

English

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

systematic review

1 reference

based on heuristic

inferred from title

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

author name string

Chris J Bushe

1

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Nicola C Savill

2

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

language of work or name

0 references

publication date

25 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

204-211

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Systematic reviews - a perspective on benefits and concerns in 2011. Safe, sound and sorted?

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Mortality in schizophrenia: a measurable clinical endpoint

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

ADHD drugs and serious cardiovascular events in children and young adults

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with n

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Cardiovascular events and death in children exposed and unexposed to ADHD agents

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Atomoxetine versus stimulants in the community treatment of children with ADHD: an electronic diary study

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113478475

21 January 2018

Identifiers

10.1177/0269881113478475

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30593927&oldid=2126759180"